Extreme responses to immune checkpoint blockade following bipolar androgen therapy and enzalutamide in patients with metastatic castration resistant prostate cancer

BACKGROUND: Immune checkpoint inhibition has been shown to have limited efficacy in patients with metastatic prostate cancer. Prostate cancers that harbor certain homologous recombination (HR) DNA repair gene mutations, inactivating CDK12 mutations or have underlying mismatch repair deficiency may b...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Prostate
Main Authors: Markowski, Mark C., Shenderov, Eugene, Eisenberger, Mario A., Kachhap, Sushant, Pardoll, Drew M., Denmeade, Samuel R., Antonarakis, Emmanuel S.
Formato: Artigo
Idioma:Inglês
Publicado em: 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7585736/
https://ncbi.nlm.nih.gov/pubmed/31972048
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pros.23955
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados